Open-label Comparative Cohort Non-interventional Epidemiological Study of the Efficacy and Safety of Enzyme Replacement Therapy in Russian Patients with Fabry Disease
Latest Information Update: 05 Jan 2026
At a glance
- Drugs Agalsidase alfa (Primary) ; Agalsidase beta (Primary) ; Agalsidase beta (Primary)
- Indications Fabry's disease
- Focus Therapeutic Use
- Acronyms FAVORIT
- Sponsors Petrovax Pharm
Most Recent Events
- 31 Dec 2025 Status changed from not yet recruiting to recruiting.
- 21 Mar 2025 New trial record